MX2021000889A - Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. - Google Patents
Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.Info
- Publication number
- MX2021000889A MX2021000889A MX2021000889A MX2021000889A MX2021000889A MX 2021000889 A MX2021000889 A MX 2021000889A MX 2021000889 A MX2021000889 A MX 2021000889A MX 2021000889 A MX2021000889 A MX 2021000889A MX 2021000889 A MX2021000889 A MX 2021000889A
- Authority
- MX
- Mexico
- Prior art keywords
- clfa
- monoclonal antibody
- aureus
- directed against
- antibody directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702762P | 2018-07-24 | 2018-07-24 | |
| PCT/US2019/043254 WO2020023644A2 (en) | 2018-07-24 | 2019-07-24 | Antibody directed against s. aureus clumping factor a (clfa) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000889A true MX2021000889A (es) | 2021-04-28 |
Family
ID=67539640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000889A MX2021000889A (es) | 2018-07-24 | 2019-07-24 | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11155606B2 (enExample) |
| EP (1) | EP3840838A2 (enExample) |
| JP (2) | JP7525471B2 (enExample) |
| KR (1) | KR102955585B1 (enExample) |
| CN (2) | CN112672788B (enExample) |
| AU (1) | AU2019309366B2 (enExample) |
| BR (1) | BR112021001214A2 (enExample) |
| MX (1) | MX2021000889A (enExample) |
| TW (1) | TWI902669B (enExample) |
| WO (1) | WO2020023644A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2917360B1 (en) | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| DE102018115012A1 (de) | 2018-06-21 | 2019-12-24 | Carl Zeiss Microscopy Gmbh | Teilchenstrahlsystem |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
| MX2021004173A (es) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
| TWI743626B (zh) | 2019-01-24 | 2021-10-21 | 德商卡爾蔡司多重掃描電子顯微鏡有限公司 | 包含多束粒子顯微鏡的系統、對3d樣本逐層成像之方法及電腦程式產品 |
| DE102019008249B3 (de) | 2019-11-27 | 2020-11-19 | Carl Zeiss Multisem Gmbh | Teilchenstrahl-System mit einer Multistrahl-Ablenkeinrichtung und einem Strahlfänger, Verfahren zum Betreiben des Teilchenstrahl-Systems und zugehöriges Computerprogrammprodukt |
| IL324469A (en) * | 2023-05-09 | 2026-01-01 | Astrazeneca Ab | Anti-Pseudomonal bispecific antibodies with modified fc regions and methods of using them |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| WO2002072600A2 (en) * | 2001-01-26 | 2002-09-19 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ATE458006T1 (de) | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| JP2009539979A (ja) | 2006-06-12 | 2009-11-19 | ナビ バイオファーマシューティカルズ | ブドウ球菌感染症を治療および予防するための、α毒素の使用 |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトｃ−ｆｍｓ抗原結合性タンパク質 |
| KR20100072228A (ko) | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| KR20110044991A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＮＦ-α 길항제 다-표적 결합 단백질 |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN102387814A (zh) | 2009-01-29 | 2012-03-21 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| AU2010251156C1 (en) | 2009-05-18 | 2015-02-05 | Julius-Maximilians-Universitat Wurzburg | Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB |
| LT3444268T (lt) | 2010-05-05 | 2022-04-11 | New York University | Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai |
| RS58190B2 (sr) | 2011-02-08 | 2021-08-31 | Medimmune Llc | Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene |
| EP3777885A1 (en) | 2011-06-19 | 2021-02-17 | New York University | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| US9962419B2 (en) | 2012-03-19 | 2018-05-08 | Tecnifar—Industria Tecnica Farmaceutica, S.A. Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections |
| ES2912267T3 (es) | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| EP2917360B1 (en) | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| CN105873946A (zh) | 2013-10-17 | 2016-08-17 | 阿尔萨尼斯生物科学有限责任公司 | 交叉反应性金黄色葡萄球菌抗体序列 |
| AU2014363987A1 (en) | 2013-12-09 | 2016-06-30 | Janssen Biotech, Inc. | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| BR112016014163A2 (pt) | 2013-12-19 | 2018-01-09 | Arsanis Biosciences Gmbh | anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado |
| JP6832709B2 (ja) | 2014-05-16 | 2021-02-24 | メディミューン，エルエルシー | 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| AU2016249837A1 (en) | 2015-04-17 | 2017-09-28 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| MX2021004173A (es) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
-
2019
- 2019-07-24 MX MX2021000889A patent/MX2021000889A/es unknown
- 2019-07-24 CN CN201980058857.XA patent/CN112672788B/zh active Active
- 2019-07-24 US US16/521,223 patent/US11155606B2/en active Active
- 2019-07-24 JP JP2021503901A patent/JP7525471B2/ja active Active
- 2019-07-24 CN CN202411220211.6A patent/CN119176871A/zh active Pending
- 2019-07-24 AU AU2019309366A patent/AU2019309366B2/en active Active
- 2019-07-24 EP EP19749544.3A patent/EP3840838A2/en active Pending
- 2019-07-24 WO PCT/US2019/043254 patent/WO2020023644A2/en not_active Ceased
- 2019-07-24 KR KR1020217005010A patent/KR102955585B1/ko active Active
- 2019-07-24 TW TW108126187A patent/TWI902669B/zh active
- 2019-07-24 BR BR112021001214-1A patent/BR112021001214A2/pt unknown
-
2021
- 2021-09-23 US US17/483,162 patent/US11970527B2/en active Active
-
2024
- 2024-03-28 JP JP2024053871A patent/JP7892714B2/ja active Active
- 2024-03-29 US US18/621,921 patent/US20240352098A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240352098A1 (en) | 2024-10-24 |
| WO2020023644A3 (en) | 2020-03-19 |
| TWI902669B (zh) | 2025-11-01 |
| CN119176871A (zh) | 2024-12-24 |
| CN112672788B (zh) | 2024-09-17 |
| AU2019309366A1 (en) | 2021-02-18 |
| CN112672788A (zh) | 2021-04-16 |
| TW202019956A (zh) | 2020-06-01 |
| EP3840838A2 (en) | 2021-06-30 |
| AU2019309366B2 (en) | 2025-06-05 |
| US11970527B2 (en) | 2024-04-30 |
| US20220073595A1 (en) | 2022-03-10 |
| WO2020023644A2 (en) | 2020-01-30 |
| KR102955585B1 (ko) | 2026-04-21 |
| JP7525471B2 (ja) | 2024-07-30 |
| BR112021001214A2 (pt) | 2021-04-27 |
| JP7892714B2 (ja) | 2026-07-21 |
| JP2021530244A (ja) | 2021-11-11 |
| CA3107463A1 (en) | 2020-01-30 |
| US20200048330A1 (en) | 2020-02-13 |
| US11155606B2 (en) | 2021-10-26 |
| KR20210035846A (ko) | 2021-04-01 |
| JP2024105229A (ja) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003535A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019) | |
| MX2024001803A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| CL2020003026A1 (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
| WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| PE20191661A1 (es) | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| MX375113B (es) | Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso. | |
| MX2019012869A (es) | Anticuerpos anti-sortilina y metodos para su uso. | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
| ECSP21022299A (es) | Anticuerpos de anti-cd33 y métodos para usarlos | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| MX2020004027A (es) | Anticuerpos especificos cd47/pd-l1. | |
| PE20200927A1 (es) | Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas | |
| CL2022000230A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| MX2018013306A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
| EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
| MX2015009819A (es) | Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo. |